FTC Gives Nod To $4.3B Dainippon-Edison Pharma Deal

Law360, Los Angeles (March 12, 2014, 5:43 PM EDT) -- The Federal Trade Commission has granted early termination to the required waiting period for a slated $4.3 billion deal between California-based Edison Pharmaceuticals Inc. and Dainippon Sumitomo Pharma Co. Ltd., the agency said in a brief notice on Tuesday.

Under the deal, which the companies announced on Jan. 31, Japan's Dainippon Sumitomo Pharma, or DSP, will partner with Edison for what the Californian company terms a strategic alliance to develop drugs targeting cellular energy metabolism. The nod closes out the waiting period required under the Hart-Scott-Rodino Antitrust...
To view the full article, register now.